ARQT — Arcutis Biotherapeutics Inc
NASDAQ · Healthcare · Biotechnology
$23.85
+$0.10 (+0.42%)
Arcutis Biotherapeutics Inc (ARQT) is a biotechnology company listed on NASDAQ. It is led by Todd Franklin Watanabe M.A., based in 3027 Townsgate Road, Westlake Village, CA, United States, 91361, with about 342 employees. Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Latest reported ARQT revenue for 2025-09-30 was $99.2M. Net income was $7.4M. Revenue was up 21.7% from 2025-06-30 to 2025-09-30. ARQT currently screens at market cap $1.64B.
Use this ARQT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ARQT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ARQT SEC filings page. Lician reads the product cache first so this HTML stays unique to Arcutis Biotherapeutics Inc even when a live quote feed is slow.
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
ARQT Key Statistics
Market Cap
$1.64B
Volume
1.90M
Previous Close
$24.86
Day Range
$24.45 – $25.50
EPS
-$1.16
Revenue
$196.54M
Net Income
-$140.04M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+229.7%
Profit Margin
-71.3%
Employees
342
ARQT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $196.54M | $59.61M | $3.69M | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$140.04M | -$262.14M | -$311.46M | -$206.36M |
| EPS (Diluted) | -$1.16 | -$3.78 | -$5.66 | -$4.18 |
Total Assets
$348.89M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$71.33M
Operating Cash Flow
-$112.16M
Free Cash Flow
$0.00
Arcutis Biotherapeutics Inc Company Information
- President, CEO & Director
- Todd Franklin Watanabe M.A.
- Headquarters
- 3027 Townsgate Road, Westlake Village, CA, United States, 91361
- Website
- www.arcutis.com
- Phone
- 805 418 5006
- IPO / Founded
- 2020-01-31
- Sector
- Healthcare
- Industry
- Biotechnology